Silence Therapeutics (SLN) said Thursday updated phase 1 trial data reinforced safety profile, efficacy and dosing convenience of divesiran as a potential treatment for polycythemia vera.
"Divesiran continues to demonstrate a very compelling profile as the first-in-class siRNA for PV," said CEO Craig Tooman.
"The Phase 2 study is over 50-percent enrolled, and we remain on-track to complete patient enrollment by the end of this year."
The data were presented at the European Hematology Association 2025 Annual Meeting in Milan, Italy, the company said.
Shares were up over 4% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.